Novavax (NVAX) Stock Price, News & Analysis

Company Overview

Novavax, Inc. is a biotechnology company focused on the discovery, development and commercialization of vaccines. The company uses its recombinant protein-based vaccine platform and Matrix-M adjuvant technology to develop vaccines designed to stimulate targeted immune responses.

Novavax’s principal commercial product is its protein-based COVID-19 vaccine, marketed in various regions under the Nuvaxovid or Novavax COVID-19 Vaccine name. The vaccine has been authorized or approved in multiple markets, including the United States, Europe and other international jurisdictions, with availability and regulatory status varying by country. Novavax has also entered into strategic arrangements with other pharmaceutical companies to support the commercialization and distribution of its COVID-19 vaccine.

Founded in 1987 and headquartered in Gaithersburg, Maryland, Novavax conducts research and development activities in the United States and works with partners and regulators internationally. Its pipeline has included vaccine candidates targeting respiratory illnesses such as influenza, respiratory syncytial virus and combination respiratory vaccines. The company is led by Chief Executive Officer John C. Jacobs.

Key Stats

• Today's Range: $12.18 to $13.25
• 50-Day Range: $7.74 to $12.82
• 52-Week Range: $6.20 to $13.39
• Volume: 7.35 million shs
• Average Volume: 5.15 million shs
• Market Capitalization: $2.11 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.14
• Consensus Rating: Hold

Novavax Stock Analysis - MarketRank™

Novavax scored higher than 35% of companies evaluated by MarketBeat, and ranked 716th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Hold

Consensus Rating

Novavax has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 5 buy ratings, 2 hold ratings, and 3 sell ratings.

Upside/Downside

The consensus price target for Novavax is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Novavax has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Novavax are expected to grow in the coming year, from ($0.38) to $0.14 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Novavax is -8.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Novavax is -8.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

28.37% of the float of Novavax has been sold short.

Short Interest Ratio / Days to Cover

Novavax has a short interest ratio ("days to cover") of 8.06.

Change versus previous month

Short interest in Novavax has recently decreased by 7.68%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Novavax does not currently pay a dividend.

Dividend Growth

Novavax does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.20

News Sentiment

Novavax has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Novavax this week, compared to 9 articles on an average week.

Search Interest

54 people have searched for NVAX on MarketBeat in the last 30 days. This is an increase of 93% compared to the previous 30 days.

MarketBeat Follows

2 people have added Novavax to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Novavax insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.60% of the stock of Novavax is held by insiders.

Percentage Held by Institutions

53.04% of the stock of Novavax is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/15/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:NVAX
• CIK: 1000694
• Web: www.novavax.com
• Phone: (240) 268-2000
• Fax: 240-268-2100
• Employees: 749
• Year Founded: 1987

Price Target and Rating

• Average Price Target for Novavax: $13.14
• High Price Target: $19.00
• Low Price Target: $6.00
• Potential Upside/Downside: +2.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.52)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $440.30 million
• Net Margins: -59.87%
• Pretax Margin: -59.28%
• Return on Equity: -14.82%
• Return on Assets: -13.35%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.33
• Quick Ratio: 2.30

Sales & Book Value

• Annual Sales: $1.12 billion
• Price / Sales: 1.88
• Cash Flow: $3.51 per share
• Price / Cash Flow: 3.65
• Book Value: ($0.79) per share
• Price / Book: -16.23

Miscellaneous

• Outstanding Shares: 164,950,000
• Free Float: 162,307,000
• Market Cap: $2.11 billion
• Optionable: Optionable
• Beta: 2.44